Insights

webinar

The objective of this webinar is to explore the QMM program and its benefits, including the rating system currently being developed by the FDA’s Center for Drug Evaluation and Research (CDER) to incentivize drug manufacturers to achieve QMM. We wi...

fact sheet

Partner with Curia for combined expertise, speed and reliability to support the research, development and manufacturing of your mRNA product.

article

For many who are new to drug development, the greatest challenge is not necessarily discovering a blockbuster molecule—it’s finding a team capable of carrying that molecule through the complexities that lie between the research lab and the patien...

publications patents

The following research articles appeared in peer-reviewed scientific journals that described innovations conceived by Curia scientists. In most of these cases, these manuscripts were written by Curia lead authors to communicate independent research...

white paper

The COVID-19 pandemic has brought the global interdependency of pharmaceutical supply chains into sharp focus, exposing weak links and re-igniting discussions around the value of reshoring production. The U.S. Food and Drug Administration (FDA) repor...

article

As the COVID-19 outbreak continues to spread across the globe, Curia is diligently monitoring the latest developments.  As such, Curia has established a companywide taskforce to assure a coordinated response across our global network, focusing on em...

publications patents

Between 2005 and 2019, there have been over 350 published pieces and nearly 300 patents that AMRI has released.

publications patents

The following research articles appeared in peer-reviewed scientific journals that described innovations conceived by AMRI scientists. In most of these cases, these manuscripts were written by AMRI lead authors to communicate independent research, or...